Alpha 2.0
Login Register
» Authors » Georg Feldmann

Georg Feldmann

Explore the profile of Georg Feldmann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 96
Citations 5766
Followers 0
Related Specialties
Oncology
Pharmacology
Nuclear Medicine
Top 10 Co-Authors
Anirban Maitra
Peter Brossart
Savita Bisht
Markus Essler
Volker Fendrich
Collins Karikari
Maria A Gonzalez-Carmona
Christian P Strassburg
Nils Habbe
Hojjat Ahmadzadehfar
Published In
Cancer Biol Ther
Mol Cancer Ther
Oncol Res Treat
J Cancer Res Clin Oncol
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
Praktiknjo M, Pena Solano A, Sadeghlar F, Welchowski T, Schmid M, Mohring C, et al.
Sci Rep . 2024 Sep; 14(1):22146. PMID: 39333610
Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with...
2.
Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature
Klein C, Jansen F, Brossart P, Herling M, Feldmann G
Case Rep Hematol . 2024 Sep; 2024:4303614. PMID: 39228413
T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10-15% of...
3.
Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic...
Marinova M, Khouri D, Kuppers J, Ramig O, Strunk H, Breuers J, et al.
J Clin Med . 2024 Jul; 13(13). PMID: 38999283
Background: Pancreatic adenocarcinoma (PaC) still has a dismal prognosis, and despite medical advances, a bleak 5-year survival rate of only 8%, largely due to late diagnosis and limited curative surgical...
4.
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer
Wang X, Breuer J, Garbe S, Giordano F, Brossart P, Feldmann G, et al.
Int J Mol Sci . 2024 Jun; 25(11). PMID: 38892436
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of human malignancies and carries an exceptionally poor prognosis. It is mostly driven by multiple oncogenic alterations, with the highest mutation...
5.
Interventional treatment of refractory non-traumatic chylous effusions in patients with lymphoproliferative disorders
Wagenpfeil J, Hoss K, Henkel A, Kutting D, Luetkens J, Feldmann G, et al.
Clin Exp Med . 2024 Mar; 24(1):63. PMID: 38554229
To report results of interventional treatment of refractory non-traumatic abdomino-thoracic chylous effusions in patients with lymphoproliferative disorders. 17 patients (10 male; mean age 66.7 years) with lymphoproliferative disorders suffered from...
6.
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
Mahn R, Gluer O, Sadeghlar F, Mohring C, Zhou T, Anhalt T, et al.
J Hepatocell Carcinoma . 2024 Jan; 11:81-94. PMID: 38239279
Background And Aim: There are several existing systemic 1st- line therapies for advanced hepatocellular carcinoma (HCC), including atezolizumab/bevacizumab (Atez/Bev), sorafenib and lenvatinib. This study aims to compare the effectiveness of...
7.
Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis
Mayer K, Serries M, Hahn-Ast C, Bisht S, Brossart P, Feldmann G
Hematology . 2023 May; 28(1):2212536. PMID: 37204122
Purpose: Therapeutic regimens and outcome of acute myeloid leukaemia (AML) patients substantially improved over the past decades. However, AML in older patients is still widely understudied and therapeutic standards are...
8.
Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years
Neidhofer C, Sib E, Neuenhoff M, Schwengers O, Dummin T, Buechler C, et al.
Antimicrob Resist Infect Control . 2023 Apr; 12(1):33. PMID: 37061726
Background: Hospitals with their high antimicrobial selection pressure represent the presumably most important reservoir of multidrug-resistant human pathogens. Antibiotics administered in the course of treatment are excreted and discharged into...
9.
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort
Mohring C, Manczak A, Timotheou A, Sadeghlar F, Zhou T, Mahn R, et al.
Int J Cancer . 2023 Mar; 153(3):609-622. PMID: 36919950
In 2019, the FLOT4 protocol was established as the new standard for perioperative therapy in patients with locally advanced gastroesophageal and gastric cancer. Whether this protocol is beneficial in a...
10.
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
Mohring C, Frontado Graffe F, Bartels A, Sadeghlar F, Zhou T, Mahn R, et al.
J Gastrointest Oncol . 2023 Mar; 14(1):352-365. PMID: 36915455
Background: Prognosis of patients with pancreatic cancer is still extremely poor. First-line palliative therapies with FOLFIRINOX or gemcitabine/nab-paclitaxel have been established in the last decade. In the second-line, 5-FU/LV in...